“Far-reaching impacts” of Federal Circuit ruling on ANDA personal jurisdiction
The Federal Circuit ruling in Acorda v Mylan and AstraZeneca v Mylan gives branded pharmaceutical companies more flexibility in their choice of where to file suit against generics
The Federal Circuit has affirmed that generic pharmaceuticals company Mylan is subject to jurisdiction in Delaware on specific jurisdiction grounds in companion cases Acorda Therapeutics v Mylan Pharmaceuticals and AstraZeneca v Mylan Pharmaceuticals.
In its ruling released on March 18,...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.